I will discuss our efforts to develop next generation laterally configured CARs which aim to bridge the gap to the attainment of effective anti-tumour activity in patients with common adult onset solid tumours. I will also discuss our off-the-shelf CAR-T programme using gamma delta T-cells armoured with granzyme B-cleavable IL-18.